Analysis of the prostate cancer transcriptome performed by us and others demonstrated that tumors harboring the TMPRSS2:ERG fusion share a unique gene expression profile which significantly differs from profiles of benign prostate tissue and malignant tumors lacking the fusion [1], [10], [12], [13], [16], [23]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.